Backs FY24 revenue view $2.55B-$2.65B, consensus $2.61B. Backs FY24 adjusted EBITDA view $580M-$620M; operating cash flow $260M-$300M; CapEx $60M-$70M.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- AMRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Amneal Pharmaceuticals announces FDA approval for OTC Naloxone HCI
- Bausch Health (NYSE:BHC) Falls 7% amid New Legal Issues
- Bausch suit creates added uncertainty on B+L spin, says TD Cowen
- Bausch Health files patent lawsuit against Amneal Pharmaceuticals